Stockscreener 앱 받기
5.20
5.05%
0.25
시간 외 거래:
5.22
0.02
+0.38%
전일 마감가:
$4.95
열려 있는:
$4.89
하루 거래량:
5.79M
Relative Volume:
0.67
시가총액:
$933.59M
수익:
-
순이익/손실:
$-25.94M
주가수익비율:
-18.12
EPS:
-0.2869
순현금흐름:
$-30.62M
1주 성능:
+3.38%
1개월 성능:
+28.71%
6개월 성능:
+219.02%
1년 성능:
+329.75%
1일 변동 폭
$4.70
$5.22
1주일 범위
$4.70
$5.69
52주 변동 폭
$0.9516
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
5.20 | 888.71M | 0 | -25.94M | -30.62M | -0.2869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SELLAS Life Sciences 2025 net loss narrows, cash position strengthens - TradingView
SLS: Strong cash position and clinical progress in AML set stage for pivotal 2026 - TradingView
[8-K] SELLAS Life Sciences Group, Inc. Reports Material Event | SLS SEC FilingForm 8-K - Stock Titan
BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million - TradingView
SELLAS Life Sciences 2025 10-K: Revenue $0.0M, EPS $(0.25) - TradingView
SELLAS nears key leukemia trial readout after raising $42.6M in Q1 - Stock Titan
[10-K] SELLAS Life Sciences Group, Inc. Files Annual Report | SLS SEC FilingForm 10-K - Stock Titan
SLS: Net loss improved to $26.9M in 2025; strong cash reserves support ongoing clinical programs - TradingView
Investment Recap: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Market WrapUp & Daily Growth Stock Tips - baoquankhu1.vn
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Sellas to present preclinical data on SLS009 at cancer conference By Investing.com - Investing.com India
Sellas to present preclinical data on SLS009 at cancer conference - Investing.com
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - The Manila Times
Experimental leukemia drug SLS009 triggers cancer cell death in lab tests - Stock Titan
Can SELLAS Life Sciences Group Inc beat the S P 500Weekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
SLS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds - Investing.com Nigeria
Sellas Life Sciences Group Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Anson Funds Management LP Has $9.71 Million Position in SELLAS Life Sciences Group, Inc. $SLS - MarketBeat
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 - Investing.com Nigeria
A Look At SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Gains - simplywall.st
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% HigherWhat's Next? - MarketBeat
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 By Investing.com - Investing.com South Africa
SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN
Sellas Says First Patient Enrolled in Phase 2 Trial of SLS009 in Acute Myeloid Leukemia - marketscreener.com
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial - Asianet Newsable
According to the latest merger agreement terms, Signature Bank shareholders will receive an equity allocation at a ratio of 2.63 shares of Esquire Financial Holdings Inc. for each share of Signature stock. - Bitget
Major Bank Ratings | Evercore ISI: Raises Ryanair target price to $80, rating upgraded to "Outperform" - Bitget
Sellas announces enrollment of first patient in Phase 2 SLS009 trial - TipRanks
SELLAS Life Sciences Group Inc. announced that the first patient has been enrolled in the clinical trial of its innovative drug SLS009 for first-line treatment of newly diagnosed acute myeloid leukemia (AML). - Bitget
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - The Manila Times
Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - marketscreener.com
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
SELLAS Strengthens Capital Base Through Warrant Exercises - TipRanks
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds By Investing.com - Investing.com Australia
SELLAS Life Sciences (NASDAQ: SLS) raises $42.6M via warrant exercises - Stock Titan
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.2%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Aug Catalysts: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s Changed - Yahoo Finance
SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month HighStill a Buy? - MarketBeat
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout - Asianet Newsable
Trade Recap: Can SELLAS Life Sciences Group Inc beat the S P 5002026 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout - Stocktwits
Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial Updates - Yahoo Finance
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
Assessing SELLAS Life Sciences Group (SLS) Valuation After New Phase 3 REGAL Trial Progress News - simplywall.st
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):